Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126797771 | 12679777 | 1 | I | 20160818 | 20160824 | 20160824 | EXP | PHHY2016BR114426 | NOVARTIS | 0.00 | M | Y | 70.00000 | KG | 20160824 | OT | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126797771 | 12679777 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 18 MG/EXELON 10 CM2 PATCH 9.5 MG QD | U | 22083 | 9.5 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | |||||
| 126797771 | 12679777 | 2 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 27 MG/15 CM2 PATCH 13.3 MG QD | U | 22083 | 13.3 | MG | TRANS-THERAPEUTIC-SYSTEM | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126797771 | 12679777 | 1 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126797771 | 12679777 | DS |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126797771 | 12679777 | Abasia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |